Estados Unidos · Plataformas y datos · MarketBeat
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom

Resumen detallado
Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event. Susie Lisa, Vertex’s seni
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




